Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Capricor Therapeutics to $38 from $43 and keeps a Buy rating on the shares. Roth notes that while it is optimistic about Deramiocel approval in Q3 and Priority Review Voucher sale in Q4, in the wake of Capricor's legal action against NS Pharma, the firm has removed the $80M milestone expected in Q4 and postponed its modeled Deramiocel U.S. launch to 2027, the analyst tells investors in a research note.
